[Federal Register Volume 86, Number 17 (Thursday, January 28, 2021)]
[Notices]
[Pages 7415-7416]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-01895]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Subcutaneous Drug Development & Delivery 
Consortium, Inc.

    Notice is hereby given that, on January 08, 2021, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug 
Development & Delivery Consortium, Inc. (``Subcutaneous Drug 
Development &

[[Page 7416]]

Delivery Consortium, Inc.'') has filed written notifications 
simultaneously with the Attorney General and the Federal Trade 
Commission disclosing changes in its membership. The notifications were 
filed for the purpose of extending the Act's provisions limiting the 
recovery of antitrust plaintiffs to actual damages under specified 
circumstances. Specifically, Sanofi, Paris, FRANCE, has been added as a 
party to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and Subcutaneous Drug Development & 
Delivery Consortium, Inc. intends to file additional written 
notifications disclosing all changes in membership.
    On October 26, 2020, Subcutaneous Drug Development & Delivery 
Consortium, Inc. filed its original notification pursuant to Section 
6(a) of the Act. The Department of Justice published a notice in the 
Federal Register pursuant to Section 6(b) of the Act on December 3, 
2020 (85 FR 78148).

Suzanne Morris,
Chief, Premerger and Division Statistics Antitrust Division.
[FR Doc. 2021-01895 Filed 1-27-21; 8:45 am]
BILLING CODE 4410-11-P